Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Eli Lilly to Acquire Morphic Holding in $3.2B Deal

Jul 8, 2024

On 8 July 2024, Eli Lilly and Morphic Holding announced that Eli Lilly has agreed to acquire Morphic for US $3.2b.  Morphic Holding is a US biopharmaceutical company developing oral integrin therapies for treating chronic diseases.  The acquisition has been approved by the boards of both companies and is expected to close in Q3/2024.

The news follows Eli Lilly’s announcement in July 2024 that the FDA has approved its Kisunla™ (donanemab-azbt) for Alzheimer’s Disease.